MX2018009100A - Metodos para modular la flora intestinal. - Google Patents

Metodos para modular la flora intestinal.

Info

Publication number
MX2018009100A
MX2018009100A MX2018009100A MX2018009100A MX2018009100A MX 2018009100 A MX2018009100 A MX 2018009100A MX 2018009100 A MX2018009100 A MX 2018009100A MX 2018009100 A MX2018009100 A MX 2018009100A MX 2018009100 A MX2018009100 A MX 2018009100A
Authority
MX
Mexico
Prior art keywords
methods
glp
defensins
intestinal microbiota
analogs
Prior art date
Application number
MX2018009100A
Other languages
English (en)
Inventor
Nordkild Peter
Wehkamp Jan
Kjærulff Søren
Original Assignee
Defensin Therapeutics Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Defensin Therapeutics Aps filed Critical Defensin Therapeutics Aps
Publication of MX2018009100A publication Critical patent/MX2018009100A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Physiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se relaciona con métodos para modular la flora intestinal al administrar una o más defensinas y/o el GLP-1/análogos del GLP-1 y con los métodos para la prevención o tratamiento de una inflamación intestinal mediante la administración oral de una o más defensinas. Los análogos del GLP-1 tales como Liraglutid, así como las alfa y beta defensinas de mamíferos y aves de corral pueden provocar un cambio en la composición de la flora y el metaboloma en el intestino y por lo tanto se pueden utilizar para tratar o prevenir una inflamación intestinal, cáncer colorrectal, síndrome metabólico, obesidad, prediabetes y diabetes o como promotores de crecimiento magro en la producción de carne.
MX2018009100A 2016-01-26 2017-01-26 Metodos para modular la flora intestinal. MX2018009100A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201670041 2016-01-26
DKPA201670483 2016-07-01
PCT/DK2017/050017 WO2017129195A1 (en) 2016-01-26 2017-01-26 Methods for modulating intestinal microbiota

Publications (1)

Publication Number Publication Date
MX2018009100A true MX2018009100A (es) 2019-02-28

Family

ID=58056942

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018009100A MX2018009100A (es) 2016-01-26 2017-01-26 Metodos para modular la flora intestinal.

Country Status (14)

Country Link
US (1) US20190111107A1 (es)
EP (1) EP3407905B1 (es)
JP (1) JP6890135B2 (es)
KR (1) KR20180121489A (es)
CN (1) CN108778309A (es)
AU (1) AU2017212534A1 (es)
BR (1) BR112018015170A2 (es)
CA (1) CA3012711A1 (es)
ES (1) ES2871117T3 (es)
MX (1) MX2018009100A (es)
RU (1) RU2738265C2 (es)
SG (1) SG11201805954WA (es)
WO (1) WO2017129195A1 (es)
ZA (1) ZA201804515B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102017219504A1 (de) 2017-11-02 2019-05-02 Bayerische Motoren Werke Aktiengesellschaft Beleuchtungsvorrichtung für ein Kraftfahrzeug
CA3082288A1 (en) * 2017-11-10 2019-05-16 Defensin Therapeutics Aps Maturation of mucosal defense and gut/lung function in the preterm infant
BR112020010180A2 (pt) * 2017-11-24 2021-01-12 Defensin Therapeutics Aps B-defensina e/ou a-defensina humana para uso na prevenção ou no tratamento de doença do enxerto contra hospedeiro aguda
CN113453701A (zh) * 2019-01-07 2021-09-28 艾斯克勒斯生物有限责任公司 用于疗法或预防法的防御素片段
CN110447763B (zh) * 2019-07-05 2023-01-20 江西农业大学 细菌在影响动物瘦肉率和/或脂肪含量中的应用
CN111202752A (zh) * 2020-02-17 2020-05-29 上海市内分泌代谢病研究所 阿克曼氏菌组合物
CN111153982B (zh) * 2020-02-17 2022-05-31 西北农林科技大学 一种反刍动物瘤胃特异抗菌肽defb1及其应用
CN111635874B (zh) * 2020-06-05 2022-03-18 江南大学 一株能够调控肠道阿克曼菌属相对丰度的脆弱拟杆菌
KR102363098B1 (ko) * 2020-06-19 2022-02-16 한국식품연구원 장내 미생물을 이용한 신질환 위험도 예측 또는 진단용 조성물, 그를 이용한 진단키트, 정보제공방법 및 신질환 예방 또는 치료제 스크리닝 방법
KR102363092B1 (ko) * 2020-06-19 2022-02-16 한국식품연구원 장내 미생물을 이용한 비만 위험도 예측 또는 진단용 조성물, 그를 이용한 진단키트, 정보제공방법 및 비만 예방 또는 치료제 스크리닝 방법
CN111938158B (zh) * 2020-08-18 2023-07-07 广东弘元普康医疗科技有限公司 一种防止肠道Akkermansia muciniphila菌丰度降低的组合物
CN112121152B (zh) * 2020-09-25 2021-06-22 南京大学 利司那肽在制备抗肿瘤药物中的应用
WO2023022631A1 (ru) * 2021-08-20 2023-02-23 Акционерное общество "БИОКАД" Способ получения модифицированного капсида аденоассоциированного вируса
CN115125167A (zh) * 2022-06-15 2022-09-30 上海交通大学医学院附属瑞金医院 微生物组合及其用途
CN114874311A (zh) * 2022-06-20 2022-08-09 成都施桂行医药科技有限责任公司 防御肽及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7528107B2 (en) * 2005-11-30 2009-05-05 Auburn University Methods of treating inflammation in mammalian tissues comprising administering human alpha-defensins
WO2007133373A2 (en) * 2006-05-01 2007-11-22 England Robert L TNF-α VACCINE FOR TREATING DISEASE CONDITIONS MEDIATED BY PATHOLOGICAL TNF-α
WO2008115390A2 (en) * 2007-03-16 2008-09-25 The Hamner Institutes For Health Sciences Methods of using defensins to treat diabetes
US20110311601A1 (en) * 2010-06-22 2011-12-22 Michael Kleine Antimicrobial medical devices
JP6219277B2 (ja) * 2011-07-08 2017-10-25 ディフェンシン セラピューティクス アンパルトセルスカブＤｅｆｅｎｓｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ａｐｓ 炎症性腸疾患の経口治療
US20130052213A1 (en) * 2011-08-19 2013-02-28 Novozymes A/S Novel immunomodulatory peptide
CN104971343B (zh) * 2015-07-13 2018-02-02 韩源平 防御素在制备治疗代谢综合征药物方面的应用

Also Published As

Publication number Publication date
JP2019504122A (ja) 2019-02-14
US20190111107A1 (en) 2019-04-18
WO2017129195A1 (en) 2017-08-03
KR20180121489A (ko) 2018-11-07
RU2018129160A3 (es) 2020-05-29
ES2871117T3 (es) 2021-10-28
SG11201805954WA (en) 2018-08-30
AU2017212534A1 (en) 2018-07-26
BR112018015170A2 (pt) 2018-12-18
CA3012711A1 (en) 2017-08-03
RU2018129160A (ru) 2020-02-27
JP6890135B2 (ja) 2021-06-18
EP3407905A1 (en) 2018-12-05
RU2738265C2 (ru) 2020-12-11
EP3407905B1 (en) 2021-02-17
CN108778309A (zh) 2018-11-09
ZA201804515B (en) 2021-01-27

Similar Documents

Publication Publication Date Title
MX2018009100A (es) Metodos para modular la flora intestinal.
PH12019501216A1 (en) New compounds as peptidic trigonal glp1/glucagon/gip receptor agonists
MX2016013244A (es) Derivados de exendina-4 como agonistas peptidicos duales del receptor de glp-1/glucagon.
MX2018000362A (es) Derivados de exendina-4 como agonistas peptidicos duales selectivos de los receptores de glp-1/glucagon.
CY1122648T1 (el) Διαδικασια για την παρασκευη συνθεσεων που περιεχουν υαλουρονικο οξυ και υδροχλωρικη μεπιβακαϊνη
MX2016013248A (es) Agonistas duales del receptor de glp-1/glucagon derivados de exendina-4.
MX2018001435A (es) Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina.
MX2016013243A (es) Agonistas peptídicos duales de los receptores de glp-1/glucagón derivados de la exendina-4.
PH12015500688A1 (en) Exendin-4 derivatives as dual glp1/glucagon agonists
MX2019006427A (es) Nuevos compuestos como agonistas peptidicos de receptores de glp1/glucagon/gip.
TR201900649T4 (tr) Oküler hastalıkların tedavisi için mrna tedavisi.
MX2015008077A (es) Derivados de exendina-4 como agonistas dobles de glp1/gip o trigonal de glp1-gip/glucagon.
MX2019013279A (es) Metodos de tratamiento del sindrome de doose utilizando fenfluramina.
PE20151808A1 (es) Peptidos terapeuticos
MX2019002265A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
EA201591687A1 (ru) Индукционная терапия ритуксимабом с последующим лечением с использованием глатирамера ацетата
BR112017007817A2 (pt) tratamento do câncer com estimuladores imunológicos
MX2016009231A (es) Administracion de tasimelteon en condiciones de ayuno.
CY1122508T1 (el) Παρασκευευασματα για θεραπεια gd2 θετικου καρκινου
ZA202001568B (en) Methods and compositions for treating chronic lung diseases
MX2020007222A (es) Metodos para el tratamiento de afecciones inflamatorias de la piel.
BR112017008621B8 (pt) Composição alimentícia para promover massa corporal magra, minimizar o ganho de gordura corporal e manter o peso sem limitar a ingestão calórica em um animal
EA202193276A1 (ru) Способы лечения холангиокарциномы
MX2020001217A (es) Metodos de tratamiento de sintomas de gastroparesia usando velusetrag.
EA201692107A1 (ru) Схема лечения тиакумициновым соединением